Kenji Ikeda

Active 1977–2025

179
Papers
33,179
Citations
91
h-index
154
i10-index

Citations

Citations per year for Kenji Ikeda1951: 1 citations1992: 2 citations1993: 8 citations1994: 34 citations1995: 50 citations1996: 43 citations1997: 46 citations1998: 75 citations1999: 115 citations2000: 118 citations2001: 114 citations2002: 112 citations2003: 126 citations2004: 137 citations2005: 142 citations2006: 115 citations2007: 156 citations2008: 163 citations2009: 199 citations2010: 265 citations2011: 191 citations2012: 235 citations2013: 245 citations2014: 226 citations2015: 230 citations2016: 212 citations2017: 248 citations2018: 287 citations2019: 1,071 citations2020: 1,347 citations2021: 1,422 citations2022: 1,068 citations2023: 807 citations2024: 1,184 citations2025: 499 citations2026: 13 citations1952–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,286 citing papers, 21.6% of this breakdownChina: 2,133 citing papers, 14% of this breakdownJapan: 1,590 citing papers, 10.4% of this breakdownItaly: 825 citing papers, 5.4% of this breakdownUnited Kingdom: 771 citing papers, 5.1% of this breakdownGermany: 738 citing papers, 4.8% of this breakdownFrance: 581 citing papers, 3.8% of this breakdownCanada: 491 citing papers, 3.2% of this breakdownSouth Korea: 478 citing papers, 3.1% of this breakdownSpain: 425 citing papers, 2.8% of this breakdownTaiwan: 356 citing papers, 2.3% of this breakdownAustralia: 330 citing papers, 2.2% of this breakdown
0%21.6%Other 21.3%

Fields

  • Medicine74.1%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Neuroscience5.5%
  • Immunology and Microbiology1.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.7%
  • Other1.9%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis8.8%
  • Liver Disease Diagnosis and Treatment5.5%
  • Hepatitis C virus research4.3%
  • Hepatitis B Virus Studies3.6%
  • Amyotrophic Lateral Sclerosis Research3.6%
  • Alzheimer's disease research and treatments3.5%
  • Other70.7%

Coauthors

All papers

Open in search
  1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2018 cited by 5,448

  2. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

    Authors: , , , , , , , , , , - Biochemical and Biophysical Research Communications 2006 cited by 2,783

  3. Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , - Cancer Research 2009 cited by 1,206

  4. UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis

    Authors: , , , , , , , , , , , , , - Nature Medicine 2017 cited by 660

  5. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Labros S. Sidossis, Francis C. Szoka, Michael T. McManus, Masayuki Saito, Tomoyoshi Soga, Shingo Kajimura - Nature 2019 cited by 543

  6. The Common and Distinct Features of Brown and Beige Adipocytes

    Authors: , , - Trends in Endocrinology and Metabolism 2018 cited by 541

  7. CD81 Controls Beige Fat Progenitor Cell Growth and Energy Balance via FAK Signaling

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cell 2020 cited by 301

  8. UCP1 Dependent and Independent Thermogenesis in Brown and Beige Adipocytes

    Authors: , - Frontiers in Endocrinology 2020 cited by 262

  9. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases

    Authors: , , , , , , , , - Journal of Neuroimmunology 2002 cited by 481

  10. Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2008 cited by 1,289

  11. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Gastroenterology 2019 cited by 227

  12. Beige Adipocyte Maintenance Is Regulated by Autophagy-Induced Mitochondrial Clearance

    Authors: , , , , , , , , , - Cell Metabolism 2016 cited by 343

  13. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

    Authors: , , , , , , , , , , , , - Hepatology 2012 cited by 709

  14. Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , - The American Journal of Gastroenterology 2011 cited by 279

  15. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis

    Authors: , , , , , , , , , , , , , , , - Nature Communications 2014 cited by 198

  16. Thermal stress induces glycolytic beige fat formation via a myogenic state

    Authors: , , , , , , , , , , , - Nature 2018 cited by 233

  17. Repression of Adipose Tissue Fibrosis through a PRDM16-GTF2IRD1 Complex Improves Systemic Glucose Homeostasis

    Authors: , , , , , , , , , , , , , - Cell Metabolism 2018 cited by 189

  18. Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

    Authors: , , , , , , , , , , , , , - Hepatology Communications 2022 cited by 49

  19. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

    Authors: , , , , , , , , , , , , , , , , - Hepatology Research 2018 cited by 107

  20. Mitochondrial lipoylation integrates age-associated decline in brown fat thermogenesis

    Authors: , , , , , , , , , - Nature Metabolism 2019 cited by 89

  21. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2022 cited by 54

  22. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

    Authors: , , , , , , , , , , , - Journal of Gastroenterology 2016 cited by 344

  23. Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

    Authors: , , , , , , , , , , , , , - Hepatology Communications 2017 cited by 104

  24. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis

    Authors: , , , , , - Brain Research 1994 cited by 166